Page last updated: 2024-09-05

sorafenib and gsk 1838705a

sorafenib has been researched along with gsk 1838705a in 2 studies

Compound Research Comparison

Studies (sorafenib)	Trials (sorafenib)	Recent Studies (post-2010) (sorafenib)	Studies (gsk 1838705a)	Trials (gsk 1838705a)	Recent Studies (post-2010) (gsk 1838705a)
6,520	730	5,251	20	0	13

Protein Interaction Comparison

Protein	Taxonomy	gsk 1838705a (IC50)
Insulin receptor	Homo sapiens (human)	0.0404
Insulin-like growth factor 1 receptor	Homo sapiens (human)	0.0998
Mitogen-activated protein kinase 8	Homo sapiens (human)	3.3407
Mitogen-activated protein kinase 10	Homo sapiens (human)	2
ALK tyrosine kinase receptor	Homo sapiens (human)	0.0005

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP	1
Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG	1

Other Studies

2 other study(ies) available for sorafenib and gsk 1838705a

Article	Year
Comprehensive analysis of kinase inhibitor selectivity. Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11 Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity	2011
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1. Cellular oncology (Dordrecht), 2018, Volume: 41, Issue:3 Topics: Actin Cytoskeleton; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Insulin-Like Growth Factor I; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Sorafenib; Vitamin K 1	2018

Article

Year

Comprehensive analysis of kinase inhibitor selectivity.

Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011

Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.

Cellular oncology (Dordrecht), 2018, Volume: 41, Issue:3

Topics: Actin Cytoskeleton; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Insulin-Like Growth Factor I; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Sorafenib; Vitamin K 1

2018